AU2001237256A1 - A method of sensitising endothelial cells to prodrugs - Google Patents

A method of sensitising endothelial cells to prodrugs

Info

Publication number
AU2001237256A1
AU2001237256A1 AU2001237256A AU3725601A AU2001237256A1 AU 2001237256 A1 AU2001237256 A1 AU 2001237256A1 AU 2001237256 A AU2001237256 A AU 2001237256A AU 3725601 A AU3725601 A AU 3725601A AU 2001237256 A1 AU2001237256 A1 AU 2001237256A1
Authority
AU
Australia
Prior art keywords
sensitising
prodrugs
endothelial cells
endothelial
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001237256A
Inventor
Jens Lichtenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2001237256A1 publication Critical patent/AU2001237256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
AU2001237256A 2000-03-08 2001-03-08 A method of sensitising endothelial cells to prodrugs Abandoned AU2001237256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000380 2000-03-08
DKPA200000380 2000-03-08
PCT/DK2001/000152 WO2001066148A1 (en) 2000-03-08 2001-03-08 A method of sensitising endothelial cells to prodrugs

Publications (1)

Publication Number Publication Date
AU2001237256A1 true AU2001237256A1 (en) 2001-09-17

Family

ID=8159306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001237256A Abandoned AU2001237256A1 (en) 2000-03-08 2001-03-08 A method of sensitising endothelial cells to prodrugs

Country Status (6)

Country Link
US (1) US20030036524A1 (en)
EP (1) EP1263474A1 (en)
JP (1) JP2003525911A (en)
AU (1) AU2001237256A1 (en)
CA (1) CA2402027A1 (en)
WO (1) WO2001066148A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US7892795B2 (en) 2005-08-02 2011-02-22 Focus Diagnostics, Inc. Methods and compositions for detecting BK virus
WO2020010249A1 (en) * 2018-07-06 2020-01-09 The Regents Of The University Of California Novel method to engineer translantable human tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2716459B1 (en) * 1994-02-22 1996-05-10 Univ Paris Curie Host-vector system usable in gene therapy.
DE19639103A1 (en) * 1996-09-24 1998-03-26 Hoechst Ag DNA construct with inhibitory mutation and corrective mutation
FR2756570B1 (en) * 1996-12-03 2002-09-27 Commissariat Energie Atomique VE-CADHERINE PROMOTER AND USES THEREOF
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism

Also Published As

Publication number Publication date
WO2001066148A1 (en) 2001-09-13
EP1263474A1 (en) 2002-12-11
US20030036524A1 (en) 2003-02-20
CA2402027A1 (en) 2001-09-13
JP2003525911A (en) 2003-09-02

Similar Documents

Publication Publication Date Title
AU2001260071A1 (en) Method for producing a solar cell, and solar cell produced according to said method
AU2001289796A1 (en) Wind power plant
AU2001221629A1 (en) Wind energy plant
AU2001252014A1 (en) Photovoltaic cell
AU2001261175A1 (en) Simplified method to produce nanoporous silicon-based films
AU2001253100A1 (en) Functional integration of multiple components for a fuel cell power plant
AU2002220097A1 (en) Method for increasing the operational efficiency of a fuel cell power plant
AU2002328303A1 (en) Method for in situ construction of a wind power plant
AU2003302941A1 (en) A process to produce an aqueous composition
AU2001264105A1 (en) A method of assembling a cell
AU2001236961A1 (en) Method of regulating transcription in a cell by altering remodeling of cromatin
AU2002359631A1 (en) Fuel cell power plant having a reduced free water volume
EP1273048B8 (en) Method of manufacturing a photovoltaic foil
AU7409801A (en) Hydroelectric plant
AU2001291632A1 (en) Method for producing a solar cell and a solar cell produced according to said method
AU2001252015A1 (en) Photovoltaic cell
GB0226029D0 (en) A fast method of transforming competent cells
AU2003263592A1 (en) Method of manufacturing a solar cell
AU2003223608A1 (en) A method to increase the rate of cell growth
AU2002322746A1 (en) Technique for removal of material to achieve a desired shape with a laser
AUPR041900A0 (en) Manipulation of plant cell walls
AU2003274658A1 (en) A method for channeling wind to produce electricity
MXPA03002858A (en) Amorphous form of cell cycle inhibitor.
AU2001237256A1 (en) A method of sensitising endothelial cells to prodrugs
AU2003210268A1 (en) Production of dadzein in transgenic plants